Larimar Therapeutics, Inc. (LRMR) Tops Q2 EPS by 7c

Larimar Therapeutics, Inc. (NASDAQ: LRMR) reported Q2 EPS of ($0.41), $0.07 better than the analyst estimate of ($0.48).

For earnings history and earnings-related data on Larimar Therapeutics, Inc. (LRMR) click here.

You May Also Be Interested In

• Deere conference call: 2027 orders up mid-single digits from last year)
• Marti Technologies (MRT) PT Raised to $6 at Benchmark on Stronger Growth, Improved Earnings Visibility
• Bernstein upgrades Analog Devices on Q3 beat, improving risk-reward